Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1Fusion-Positive Cancers

Autor: Odintsov, Igor, Mattar, Marissa S., Lui, Allan J.W., Offin, Michael, Kurzatkowski, Christopher, Delasos, Lukas, Khodos, Inna, Asher, Marina, Daly, Robert M., Rekhtman, Natasha, de Stanchina, Elisa, Ganji, Gopinath, Ladanyi, Marc, Somwar, Romel
Zdroj: Journal of Thoracic Oncology; 20210101, Issue: Preprints
Abstrakt: NRG1rearrangements produce chimeric ligands that subvert the ERBB pathway to drive tumorigenesis. A better understanding of the signaling networks that mediate transformation by NRG1fusions is needed to inform effective therapeutic strategies. Unfortunately, this has been hampered by a paucity of patient-derived disease models that faithfully recapitulate this molecularly defined cancer subset.
Databáze: Supplemental Index